The discovery of new strategies for chemotherapeutic agents to promote the expansion and differentiation of CD62L+ Tpex cells into antitumor effector-functional Texint cells may help improve the longevity and efficacy of T cell therapy in clinical cancer. Here, SELL is linked to cancer.